Immuneering (IMRX) announced that it will host a conference call and webcast on January 7, 2026 to provide an update on 12-month overall survival from its ongoing Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel, mGnP, in first-line pancreatic cancer patients. “We are excited to share updated overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “We are increasingly confident in atebimetinib’s ability to extend and improve the lives of patients with pancreatic cancer.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering on track to dose first patient in pancreatic cancer trial in 2026
- Immuneering to be added to the Nasdaq Biotechnology Index
- Immuneering Corp. Shines in Positive Earnings Call
- Promising Potential of Immuneering’s Atebimetinib: Analyst Recommends ‘Buy’ Rating
- Immuneering Corp. Reports Strong Q3 2025 Progress